Physician profile
Bhanu Iyer
NPI 1730287269
$2,986.39
in general payments reported to CMS, 2019-2025
30 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2021: $73.50 · 2022: $59.63 · 2023: $539 · 2024: $803 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,598.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $414.46 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $387.50 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Dexcom, INC. | $304.55 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $206.88 | 2023-2025 | |
| Abbott Laboratories | $197.57 | 2022-2025 | Freestyle Libre |
| Xeris Pharmaceuticals, INC. | $160.60 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Abbvie INC. | $158.71 | 2024-2025 | |
| Medtronic, INC. | $155.22 | 2022-2025 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $143.53 | 2019-2025 | |
| Novo Nordisk INC | $132.46 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Ibsa Pharma INC. | $105.21 | 2023-2025 | Tirosint, Licart, Tirosint |
| Insulet Corporation | $91.58 | 2024-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $68.25 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $64.50 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $49.87 | 2025 | Contrave |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $45.17 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $37.41 | 2019 | |
| Amneal Pharmaceuticals LLC | $33.93 | 2024-2025 | Unithroid |
| Beta Bionics, INC. | $27.13 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Medtronic Minimed, INC. | $25.74 | 2019 | |
| Valeritas, INC. | $23.08 | 2019 | |
| Alvogen INC | $21.70 | 2025 | Teriparatide |
| Pfizer INC. | $21.41 | 2024 | |
| Pharmacosmos Therapeutics INC. | $18.98 | 2025 | Monoferric |
| Embecta Corp. | $17.84 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Alexion Pharmaceuticals, INC. | $15.83 | 2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $15.82 | 2025 | Yorvipath |
| Acella Pharmaceuticals, LLC | $15.40 | 2024 | NP Thyroid 60 |
| Azurity Pharmaceuticals, INC. | $13.61 | 2023 | Adthyza |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhanu Iyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.